Pamela Lockyer

OverviewAI-generated summary

Pamela Lockyer investigates molecular mechanisms underlying hematological malignancies, particularly myelodysplastic syndromes (MDS) and multiple myeloma. Her research focuses on identifying novel therapeutic targets and understanding disease progression at the cellular and molecular level. She has published work examining stem cell architecture in MDS, exploring how it influences disease progression and predicts response to therapies like venetoclax. Her studies also investigate hematopoiesis under conditions of telomere attrition, providing single-cell resolution insights.

Lockyer's group has explored specific signaling pathways, such as the EIF2AK1 pathway, to rescue red blood cell production in MDS with specific genetic mutations (SF3B1). Additionally, her work has delved into overcoming metabolic reprogramming in multiple myeloma through targeting pathways like DNA2. She has also contributed to understanding transcriptomic signatures associated with treatment failure in MDS and chronic myelomonocytic leukemia, and the role of UBA1 expression in myelodysplastic neoplasms.

Her scholarly contributions include 81 publications with an h-index of 19 and 1,395 citations. Lockyer is a Co-Principal Investigator on a grant from the NIH/National Cancer Institute focused on the drug development of Skp2 PROTACs in cancer. She collaborates with researchers at the University of Arkansas for Medical Sciences, including Samrat Roy Choudhury and Cam Patterson.

Metrics

• h-index: 19
• Publications: 81
• Citations: 1,395